United States: EYLEA® Proposed Biosimilar M710 BPCIA Appeals Dismissed For Lack Of Jurisdiction - Venable LLP

United States: EYLEA® Proposed Biosimilar M710 BPCIA Appeals Dismissed For Lack Of Jurisdiction - Venable LLP

Mondaq

Published

On April 12, 2024, the Federal Circuit dismissed CAFC Appeal No. 24-1402 and Cross-Appeal No. 24-1405 for lack of jurisdiction following its February 22, 2024 order directing Regeneron and Mylan / Biocon.

Full Article